Abstract:Abstract Background Some cytokine signaling pathways can interact with interferon (IFN)-α pathway and thus regulate cell responses to IFN-α. Levels of the pro-inflammatory cytokine interleukin-17A (IL-17A) were found to be elevated in both the peripheral blood and liver in chronic hepatitis B (CHB) patients. However, how IL-17A affects the anti-HBV activity of IFN-α remains unclear. Methods The effects of IL-17A on anti-HBV activity of IFN-α were evaluated in HBV-expressing HepG2 cells (HepG2-HBV1.3) with IL-17A pretreatment and IFN-α stimulation. Culture supernatant levels of HBsAg, HBeAg, and HBV DNA, or intracellular expression of HBsAg and HBcAg were detected by ELISA, real-time quantitative PCR (RT-qPCR), or western blotting (WB). The expression of canonical IFN-α signaling pathway components, including the interferon-α/β receptor (IFNAR), Janus Kinase 1 (JAK1), Tyrosine Kinase 2 (TYK2), the Interferon Stimulated Gene Factor 3 complex (ISGF3) and IFN-stimulated genes (ISGs), was also examined by RT-qPCR, Immunofluorescence or WB. The effects of IL-17A were further investigated by the suppression of the IL-17A pathway with a TRAF6 inhibitor. Results Compared to IFN-α stimulation alone, IL-17A pretreatment followed by IFN-α stimulation increased the levels of HBsAg, HBeAg, and HBV DNA, and decreased the levels of ISGF3 complex (phosphorylated (p)-signal transducer and activator of transcription (STAT1)/p-STAT2/IRF9) and antiviral-related ISGs (ISG15, ISG20 and Mx1). Interestingly, IL-17A pretreatment increased the expression of suppressor of cytokine signaling (SOCS) 1, SOCS3 and USP18, which were also the ISGs negatively regulating activity of ISGF3. Moreover, IFNAR1 protein expression declined more sharply in the group with IL-17A pretreatment than in the group with IFN-α stimulation alone. Blocking the IL-17A pathway reversed the effects of IL-17A on the IFN-α-induced activation of ISGF3 and anti-HBV efficacy. Conclusions Our results demonstrate that IL-17A pretreatment could attenuate IFN-α-induced anti-HBV activity by upregulating negative regulators of the critical transcriptional ISGF3 complex. Thus, this might be a potential target for improving response to IFN-α therapy.

Ubiquitin Specific Protease 18 Inhibits the Anti-Hepatitis B Virus Activity of Interferon-Alpha, but Does Not Inhibit Interferon-Lambda in HepG2.2.15 Cells

Suppression of USP18 Potentiates the Anti-HBV Activity of Interferon Alpha in HepG2.2.15 Cells Via JAK/STAT Signaling

USP18attenuates the Anti-Hepatitis B Virus Effect of IFN by Down Regulating JAK-STAT Pathway

Transcriptional Response of USP18 Predicts Treatment Outcomes of Interferon-Alpha in HBeAg-positive Chronic Hepatitis B Patientsefere

Gene expression profile after knockdown of USP18 in Hepg2.2.15 cells.

The role of USP 18 in interferon signaling and inflammation

The Ubiquitin-Specific Protease 18 Promotes Hepatitis C Virus Production by Increasing Viral Infectivity

IFN-λ4 desensitizes the response to IFN-α treatment in chronic hepatitis C through long-term induction of USP18.

Ifn-Lambda 4 Desensitizes The Response To Ifn-Alpha Treatment In Chronic Hepatitis C Through Long-Term Induction Of Usp18

Downregulation of USP18 Inhibits Growth and Induces Apoptosis in Hepatitis B Virus-Related Hepatocellular Carcinoma Cells by Suppressing BCL2L1

Level Changes and Clinical Significance of Plasma IL-18,IP-10 in Patients with Chronic Hepatitis B During Antiviral Treatment

USP18 Mediates Interferon Resistance of Dengue Virus Infection

Interferon Stimulated Exonuclease Gene 20 Kda Promotes The Activity Of Interferon-Alpha On The Inhibition Of Hepatitis B Virus Replication Via Its Exonuclease Activity

Inhibition of Hepatitis B Virus Gene Expression by Single and Dual Small Interfering RNA Treatment

[The Influence of HBV and Its Antigens on the Expressions of JAK-STAT Signal Transduction Pathway Molecules and Antiviral Proteins of IFN Alpha].

Inhibition of hepatitis B virus replication by VPS4B dominant negative mutant

Hepatitis B Virus Polymerase Impairs Interferon-Α-induced STA T Activation Through Inhibition of Importin-Α5 and Protein Kinase C-δ

Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells

Functional Comparison of Interferon- Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon- and Interferon- Signaling

Different Antiviral Effects of IFNα and IFNβ in an HBV Mouse Model.

Susceptibility of Different Hepatitis B Virus Isolates to Interferon-Alpha in a Mouse Model Based on Hydrodynamic Injection.